Arrowhead & Sarepta Sign a Global Licensing and Collaboration Agreement for Multiple Clinical and Preclinical Programs
Shots:
- In next 5yrs., Sarepta will select 6 targets in CNS or muscle for development and commercialization whereas, Arrowhead will handle discovery, preclinical and manufacture clinical drug supply for them & for 4 commercial products currently in clinical trials
- Arrowhead to get $825M upfront ($500M cash + $325M equity), $250M in annual tranches ($50M for 5yrs.), $300M on complete enrolment of P-I/II in 12mos., ~$10B milestones ($110-$410M development + $500-$700M sales milestones per program) & low double digit tiered royalties
- P-I/II clinical programs are ARO-DUX4 (FSHD1), ARO-DM1 (DM1), ARO-MMP7 (IPF) & ARO-ATXN2 (SCA2); preclinical programs are ARO-HTT (HD, CTA-ready by 2025), ARO-ATXN1 (SCA1) & ARO-ATXN3 (SCA3), both CTA-ready by 2026
Ref: Arrowhead | Image: Arrowhead & Sarepta
Related News:- Arrowhead and Janssen Entered into a Licensing Agreement with GSK for JNJ-3989 to Treat Chronic Hepatitis B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
